NCT07660796Not yet recruitingPhase 3
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 256 (estimated)
- First submitted
- 16 Jun 2026
- Start date
- 6 Jul 2026
- Primary completion date
- 30 Oct 2027
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Diseases
- High blood pressure
- NCT number
- NCT07660796
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 256
- From 6 Jul 2026 to the primary completion date, 30 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
- Orthostatic hypotension with symptoms within 3 months prior to visit 1
Other illness
- Severe heart disease or severe neurovascular disease
- Moderate or malignant retinopathy
- Uncontrolled diabetes mellitus or type I diabetes mellitus
- Severe renal diseases
- History of malignancy tumor
- History of autoimmune disease
- History of alcohol or drug abuse
Other
- Difference between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP at Visit 1
- Secondary hypertensive patient or suspected to be
- Clinically significant hematological finding
- Active gout or hyperuricemia
- Severe or active hepatopathy
- Hypokalemia or Hyperkalemia
- Hyponatremia or Hypernatremia
- Hypercalcemia
- Positive to pregnancy test, nursing mother, intention on pregnancy
- Considered by investigator as not appropriate to participate in the clinical study with other reason
Who the study is looking for
- Patients with essential hypertension whose blood pressure measured in visit1 corresponds to the following conditions
- mean sitSBP \< 180 mmHg and mean sitDBP \< 110 mmHg for patients receiving any BP-lowering drug within 1 month prior to Visit 1
- 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg for patients not receiving BP-lowering drugs within 1 month prior to Visit 1
- Patients with essential hypertension who meet 140 mmHg ≤ mean sitSBP \< 180 mmHg and 60 mmHg ≤ mean sitDBP \< 110 mmHg at Visit 2
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Donggguk University Ilsan Hospital Coordinator of this site? Confirm its status | Goyang-si | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.